Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also approved in the European Union. Nerlynx in combination with Roche's Xeloda was approved?by the Food and Drug Administration for third-line HER2-positive metastatic breast cancer. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations as well as other types of cancers are currently underway. A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers. Puma markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.
| Revenue (Most Recent Fiscal Year) | $230.50M |
| Net Income (Most Recent Fiscal Year) | $30.28M |
| PE Ratio (Current Year Earnings Estimate) | 7.86 |
| PE Ratio (Trailing 12 Months) | 4.39 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.72 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.73 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.97 |
| Pre-Tax Margin (Trailing 12 Months) | 13.73% |
| Net Margin (Trailing 12 Months) | 16.37% |
| Return on Equity (Trailing 12 Months) | 49.35% |
| Return on Assets (Trailing 12 Months) | 18.25% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.11 |
| Inventory Turnover (Trailing 12 Months) | 8.80 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $0.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.77 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 49.63M |
| Free Float | 37.87M |
| Market Capitalization | $167.75M |
| Average Volume (Last 20 Days) | 0.36M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.29% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |